Capricor's Deramiocel BLA Rejected Again: FDA CRL Confirms Bear Case
Read source articleWhat happened
On November 20, 2026, Capricor announced the FDA issued a Complete Response Letter for its resubmitted BLA for deramiocel in DMD, citing insufficient evidence of effectiveness and other clinical deficiencies. This confirms the bear scenario outlined in our prior report, which assigned a 35% probability to a CRL and an implied value of $4.50 per share. The agency's rejection directly contradicts management's salvage thesis that 24-month open-label extension data and a refined upper-limb endpoint would support approval. With no revenue, annualized cash burn near $120 million, and roughly $238 million in cash at June 30, 2026, the company now faces a longer regulatory path likely requiring new clinical trials and further dilution. The unresolved Nippon Shinyaku commercial dispute and prior BIMO Form 483 observations add operational and legal overhang to an already damaged narrative.
Implication
Investors should treat the CRL as a thesis breaker: the FDA has now twice found insufficient evidence, and the open-label extension data were never alpha-controlled or powered to support approval. The stock is likely to reprice toward the bear-case implied value of $4.50, but near-term downside could overshoot if management's next step involves a new pivotal study and a multi-year delay. Cash of $237.9 million at June 30, 2026 provides roughly two years of runway at current burn, but without a clear regulatory path, that cash will be consumed defending the asset rather than creating value. The Nippon Shinyaku arbitration further clouds any future commercial economics, and unless Capricor can quickly articulate a feasible path forward—perhaps a narrowly defined subgroup or alternative endpoint—investor confidence will remain impaired. We would not re-enter until there is concrete FDA guidance on what additional evidence would be sufficient and a realistic financing plan to get there.
Thesis delta
Our prior thesis was conditional on FDA approving a narrow upper-limb label by November 22, 2026; that condition has failed. The CRL confirms the bear scenario and shifts the thesis from regulatory salvage to a cash-burn platform story with no near-term approvable asset. We downgrade from WAIT to SELL, with fair value now anchored to the bear case of $4.50 per share, reflecting the need for new clinical trials, dilution, and unresolved commercial disputes.
Confidence
High